Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAO1 | Q9UJM8 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | F7 | P08709 | 1/20 | 0.36 |
| ▸ | F3 | P13726 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | PAK4 | O96013 | 3/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22816548 | 0.81 | HAO1 (0.41) | HAO1POLBF7F3NPC1 | |
| SCHEMBL30631902 | 0.81 | HAO1 (0.41) | HAO1POLBF7F3NPC1 | |
| SCHEMBL29514605 | 0.79 | JAK2 (0.42) | HAO1POLBPIM1PIM2KCNH2 | |
| SCHEMBL22608602 | 0.79 | JAK2 (0.42) | HAO1POLBPIM1PIM2KCNH2 | |
| SCHEMBL22608613 | 0.76 | PTGES (0.40) | HAO1F7F3FAAH | |
| SCHEMBL30631900 | 0.76 | CXCL8 (0.43) | HAO1POLBHDAC1HDAC2KCNH2 | |
| SCHEMBL22816862 | 0.76 | CXCL8 (0.43) | HAO1POLBHDAC1HDAC2KCNH2 | |
| Trifluoroacetic Acid SCHEMBL29490660 | 0.75 | GPR6 (0.37) | HAO1POLBF7F3PIM1 | |
| Trifluoroacetic Acid SCHEMBL22608824 | 0.75 | GPR6 (0.37) | HAO1POLBF7F3PIM1 | |
| SCHEMBL11334107 | 0.74 | MEN1 (0.49) | HAO1POLBRAB9AHDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117126152-A | Glycolate oxidase inhibitors for use in the treatment of disease | 生物马林药物股份有限公司 | 2023-11-28 | — | — | CN | disclosed |
| CN-117126151-A | Glycolate oxidase inhibitors for use in the treatment of disease | 生物马林药物股份有限公司 | 2023-11-28 | — | — | CN | disclosed |
| CN-117069712-A | Glycolate oxidase inhibitors for use in the treatment of disease | 生物马林药物股份有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-117069713-A | Glycolate oxidase inhibitors for use in the treatment of disease | 生物马林药物股份有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-117024420-A | Glycolate oxidase inhibitors for use in the treatment of disease | 生物马林药物股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| US-20230088214-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230089374-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230079913-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| EP-3986863-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BioMarin Pharmaceutical Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-114258390-A | Glycolate oxidase inhibitors for disease treatment | 生物马林药物股份有限公司 | 2022-03-29 | — | — | CN | disclosed |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-06-10 | — | — | US | disclosed |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2020257487-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020257487-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| EP-3732167-A2 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BioMarin Pharmaceutical Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
| CN-111788187-A | Glycolate oxidase inhibitors for disease treatment | 生物马林药物股份有限公司 | 2020-10-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230079913-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | HAO1 9/4885POLB 870/4885F7 2849/4885 |
| US-20230088214-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | HAO1 10/4885POLB 851/4885F7 2982/4885 |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | HAO1 9/4885POLB 870/4885F7 2849/4885 |
| US-20230089374-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | HAO1 9/4885POLB 870/4885F7 2849/4885 |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | HAO1 9/4885POLB 870/4885F7 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.